Testing the Safety and Efficacy of Commercial Drug Biktarvy in Subjects Known to Have the 184 Resistance Mutation to a Component in Biktarvy

NCT04040075 · clinicaltrials.gov ↗
PHASE4
Phase
TERMINATED
Status
12
Enrollment
OTHER
Sponsor class

Stopped Unable to complete enrollment goals due to unanticipated factors of screen failures, covid pandemic, and continued staffing and enrollment difficulties

Conditions

Interventions

Sponsor

Southampton Healthcare, Inc.